Pharmaceutical company Merck announced its second-quarter Prevymis sales figures. The revenue generated from Prevymis reached $295 million, representing a 29% increase primarily due to higher demand in the U.S. and certain European markets.
This growth can be attributed in part to the launch of new indications for Prevymis, which has expanded its market reach.
More on Stocks
Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.
Real-time market sentiment intelligence for apps, funds & agents
Location
729 55 Ave SW
Calgary AB T2V 0G4
Canada
© 2026 Guavy Inc
